Introduction {#s1}
============

Pneumonia and meningitis continue to be an enormous public health burden. According to the Global Burden of Disease 2015 study, more than 3.1 million deaths due to pneumonia and meningitis were estimated to have occurred in 2015. The two diseases together accounted for more than 15% of deaths in children under 5 years of age. Bacteria, viruses, and fungi can all cause pneumonia and meningitis, but bacteria are the leading cause of serious disease and deaths (GBD 2015 Mortality and Causes of Death Collaborators, [@B13]). For bacterial pathogens, the selection of appropriate antibiotics forms the basis of sound clinical management. However, this complex etiology and overlapping clinical presentations make it challenging to identify the causative organism.

Culture-based microbiological methods are routinely used to determine the responsible pathogen, but a long turn-around time and low sensitivity reduce their utility in making timely decisions (Prina et al., [@B35]). Even with an advanced automated bacteria identification system, nearly 20 h of processing time is needed (Bobenchik et al., [@B4]; Jacobs et al., [@B18]). Moreover, additional time and labor are necessary for pathogens that grow slowly, such as *Legionella pneumophila* and *Mycoplasma pneumoniae* (Atkinson et al., [@B2]; Mercante and Winchell, [@B25]). To avoid the drawbacks of culture-based approaches, molecular testing has been widely applied, providing an important complement to bacterial culture. Molecular detection is faster, more sensitive, and can be automated. In addition, several emerging technologies such as multiplex real-time PCR and microarray methods are available for clinical application (Buchan and Ledeboer, [@B5]).

MassARRAY System (Agena Bioscience, Inc., San Diego, CA, USA), a detection platform combining matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) with endpoint PCR, has been successfully applied in the field of microbial detection (Syrmis et al., [@B36]; Li et al., [@B22]; Peng et al., [@B30],[@B33], [@B32], [@B31]; Zhang et al., [@B41]). Taking advantage of the system\'s multiplex capability and high sample throughput, we developed and validated a bacterial pathogen-MS panel (BP-MS) to simultaneously screen 11 key bacterial pathogens associated with pneumonia and meningitis, including *Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Moraxella catarrhalis, L. pneumophila, M. pneumoniae*, and *Bordetella pertussis*. To evaluate the effectiveness of the BP-MS method, we tested 204 clinical respiratory tract samples. Real-time PCR and nested PCR were used to confirm the results.

Materials and methods {#s2}
=====================

Specimens
---------

Using PCR and Sanger sequencing, 46 stock nasopharyngeal swabs were determined positive for target pathogens and used in the validation stage (data not shown). Isolates were also included in this validation stage. The 204 nasopharyngeal swabs used in the evaluation stage were collected from children hospitalized with suspected pneumonia in Beijing Children\'s Hospital in 2014. The swab samples were collected before antibiotic treatment.

DNA extraction
--------------

All of the nasopharyngeal swabs were collected according to a standard protocol in general bacteria collection tubes with maintenance medium (Yocon, Beijing, China) and then stored at −80°C. For DNA extraction, samples were thawed at room temperature, 200 μl of maintenance medium was added, and the mixture was centrifuged at 5,000 × *g* for 10 min. The bacterial pellets were then resuspended in 150 μl of enzyme cocktail containing 30 U of lysostaphin, 6 mg of lysozyme, 37.5 U of mutanolysin, and 30 U of lyticase (Millipore Sigma, Darmstadt, Germany) in lysis buffer with working concentrations of 20 mM Tris-HCI (pH 8), 2 mM EDTA, and 1.2% Triton. To lyse the rigid cell walls of gram-positive bacteria, the resuspended bacteria were incubated at 37°C for 30 min. After incubation, 20 μl of proteinase K and 200 μl of buffer AL (QIAgen, Hilden, Germany) were added, and the mixture was incubated for 20 min at 56°C and then 15 min at 95°C. Finally, the DNA was purified using a QIAamp DNA Mini Kit (QIAgen, Hilden, Germany) according to the user\'s guide.

Assay design
------------

To design the assay, we used Assay Design 4.0 software (Agena Bioscience, Inc., San Diego, CA, USA) according to the user\'s manual. For each of the 11 pathogens, a target gene was chosen to design the detection assays. Human β-globin (HBB) was selected as an internal control, and BLASTn was used to check the specificity of each target gene. For each target gene, sequences in GenBank database were downloaded and aligned. Conserved regions were chosen to design the assays. In each assay, forward and reverse PCR primers were used to amplify the template and an extension primer was used for single base extension (SBE) reaction. To avoid interference in the mass spectra, a 10-base mass tag (ACGTTGGATG) was added to the 5′ end of each PCR primer. PCR and extension primers were synthesized by Tsingke Biological Technology (Beijing, China).

Primary multiplex PCR and dephosphorylation reaction
----------------------------------------------------

Twelve pairs of PCR primers were pooled and then mixed with hot start PCR enzyme, PCR buffer, MgCl~2~ (Agena Bioscience, Inc.), uracil-DNA glycosylase (ShineGene Molecular Biotechnology, Shanghai, China), dNTP (dATP, dGTP, dCTP, and dUTP) (Promega, Madison, WI, USA), and 2 μl of DNA template for a 5-μl total volume. The multiplex PCR was performed in 384-well PCR plates using a ProFlex PCR system (Applied Biosciences, Foster City, CA, USA). The reaction conditions for the multiplex PCR were as follows: 45°C for 2 min; 94°C for 4 min; 95°C for 2 min; 45 cycles of 95°C for 30 s, 56.5°C for 30 s, and 72°C for 1 min; and 72°C for 5 min. After amplification, shrimp alkaline phosphatase (SAP) (Agena Bioscience, Inc.) was used to dephosphorylate excess dNTP at 37°C for 40 min, and then the SAP was inactivated at 85°C for 5 min.

SBE reaction and MS
-------------------

Following the dephosphorylation reaction, an SBE reaction was performed using the iPlex Pro SBE system (Agena Bioscience, Inc.) with a mixture of 12 extension primers according to the user\'s manual. During this process, the extension primers bound to the amplicons generated in the primary multiplex PCR and incorporated one terminator nucleotide. After exchanging salts with resin, the SBE reaction products were transferred to a 384 silica array preloaded with matrix (Agena Bioscience, Inc.) and then analyzed by mass spectrometry. If an extension primer incorporated a terminator nucleotide, a peak representing the extended extension primer appeared at the expected mass. The peak height representing the original extension primer was reduced. Based on the mass spectrum, the template could be identified. The detailed procedure with reagent concentrations and reaction conditions can be found in previous reports (Zhang et al., [@B41]; Xiu et al., [@B40]).

Real-time PCR and nested PCR methods used as confirmatory tests
---------------------------------------------------------------

Real-time PCR was performed to confirm positive results from the BP-MS method. For *S. pneumoniae, H. influenzae, S. aureus, M. catarrhalis, K. pneumoniae, A. baumannii*, and *P. aeruginosa*, multiplex real-time PCR was used (Gadsby et al., [@B12]). For *N. meningitidis, L. pneumophila, M. pneumoniae*, and *B. pertussis*, singleplex real-time PCR was used according to previously published methods (Corless et al., [@B9]; Welti et al., [@B39]; Tatti et al., [@B37]). Each sample was tested in duplicate and regarded as positive if both cycle threshold (CT) values were \<40. Nested PCR methods were used to resolve disagreements between results of the BP-MS and real-time PCR methods. The nested PCR was designed in-house for this study and was based on published conventional PCR assays. The primers and probes used in the confirmatory tests described above are listed in Tables [S2](#SM2){ref-type="supplementary-material"}, [S3](#SM3){ref-type="supplementary-material"} in the Supplementary Material.

Statistical analysis
--------------------

Differences in the concordance rates of results for multiple-infection samples and single-infection samples were χ^2^-tested. A *p*-value \<0.05 was considered statistically significant.

Ethics approval
---------------

The study was performed in accordance with the recommendations of national ethics regulations and approved by the Institutional Review Board of the Institute of Pathogen Biology. All participants provided written informed consent in accordance with the Declaration of Helsinki. For children, written informed consent was obtained from parents or guardians.

Results {#s3}
=======

BP-MS method
------------

In this study, we developed a 12-plex method to simultaneously detect 11 key bacterial pathogens associated with pneumonia and meningitis, using HBB as a nucleic acid extraction control. On the basis of previously published studies, we chose well-characterized and highly sensitive and specific genes as targets. *In silico* analysis showed that the BP-MS method can be used to specifically detect target pathogens, including most strains within a species. The final target genes and assays are listed in Table [S1](#SM1){ref-type="supplementary-material"} in the Supplementary Material.

Validation of specificity and sensitivity
-----------------------------------------

Specificity of the method was validated by testing 58 confirmed clinical samples and isolates (Table [1](#T1){ref-type="table"}). The results showed that the BP-MS method can be used to accurately identify the expected bacteria without cross-reactivity with non-target pathogens (Figures [S1](#SM4){ref-type="supplementary-material"}, [S2](#SM5){ref-type="supplementary-material"} in the Supplementary Material). Plasmids containing the target genes of each pathogen were 10-fold diluted and used to evaluate the analytical sensitivity of the BP-MS method. Based on the results, the BP-MS method can be used to determine the concentration of corresponding plasmids with 10 copies per reaction (Figure [1](#F1){ref-type="fig"}).

###### 

Sequencing confirmed nasopharyngeal swabs and isolates used for validating specificity.

  **Target bacteria**          **No. of confirmed swabs**   **No. of isolates**   **Total**
  ---------------------------- ---------------------------- --------------------- -----------
  *Streptococcus pneumoniae*   7                            0                     7
  *Haemophilus influenzae*     6                            1                     7
  *Neisseria meningitidis*     2                            2                     4
  *Klebsiella pneumoniae*      3                            2                     5
  *Acinetobacter baumannii*    3                            1                     4
  *Pseudomonas aeruginosa*     3                            1                     4
  *Staphylococcus aureus*      6                            0                     6
  *Moraxella catarrhalis*      5                            1                     6
  *Legionella pneumophila*     0                            4                     4
  *Mycoplasma pneumoniae*      7                            0                     7
  *Bordetella pertussis*       4                            0                     4
  Total                        46                           12                    58

![Mass spectrum of sensitivity evaluation by using 10-fold diluted plasmids. Figures **(A--L)** represents the mass spectra of each target by analyzing plasmids at 10 copies/reaction. The left arrow indicates the consumed unextended primer and the right arrow indicates the extended primer. The x-axis represents the mass of extension primer and the y-axis represents the intensity.](fcimb-08-00107-g0001){#F1}

Evaluation of the BP-MS method performance with clinical samples
----------------------------------------------------------------

A total of 204 nasal and throat swabs were collected to evaluate the performance of the BP-MS method. Each of the 11 target pathogens was detected, with an overall detection rate of 81.9% (167/204). Among all the 167 pathogen-positive samples, the rate of infection with multiple pathogens was 55.7% (93/167). Two and three pathogens were detected in 47 and 29 samples, respectively, whereas four or five pathogens were detected in 17 samples.

Samples determined pathogen-positive by the BP-MS method were re-tested first by real-time PCR. Using a combination of multiplex and singleplex real-time PCRs, 46.1% (77/167) of the positive samples showed results concordant with those from the BP-MS method. Compared with the BP-MS method, 56.8% (42/74) of the single-infection samples showed concordant results, but for multiple infection samples, the concordance rate was only 37.6% (35/93). These concordance rates differed significantly (*p* = 0.014 by χ^2^-test). The discordant samples were further confirmed by nested PCR followed by sequencing of PCR products. Combining results of the real-time and nested PCRs, the BP-MS method and confirmatory tests showed 81.4% (136/167) concordance, with verification rates for each target pathogen ranging from 50% (*L. pneumophila*) to 100% (*B. pertussis*) (Table [2](#T2){ref-type="table"}). For single-infection samples, the overall verification rate was 81.1% (60/74), whereas this rate was 81.7% (76/93) for multiple-infection samples. The difference between these two rates was not statistically significant (*p* = 0.92 by χ^2^-test). The most frequent combination in multiple-pathogen infections was *S. pneumoniae* with *H. influenzae*, which accounted for 46.2% (43/93) of mixed infections. All combinations of multiple infections that were verified by confirmatory tests in this study are listed in Table [3](#T3){ref-type="table"}. Thirty-one BP-MS-positive samples were not verified by either real-time PCR or nested PCR. Of these, 14 were single-infection samples and 17 were multiple-infection samples. All single-infection samples tested negative by both confirmatory tests, and, for 13 of 17 multiple-infection samples, one of the targets was not confirmed. For single-infection samples, *S. pneumoniae* was the pathogen most commonly unconfirmed (*n* = 9) whereas for multiple-infection samples, *K. pneumoniae* was the pathogen most commonly unconfirmed (*n* = 7). Details of the 31 discordant samples are shown in Table [4](#T4){ref-type="table"}.

###### 

Results of confirmatory tests of positive samples by the BP-MS method.

  **Target bacteria**                     **No. (%) of positive samples by BP-MS**   **No. of samples confirmed by real-time PCR/No. of positive samples by BP-MS**   **Verification rate (%) of real-time PCR**   **No. of discordant samples confirmed by nested PCR**   **No. of overall confirmed samples**   **Overall verification rate (%)**
  --------------------------------------- ------------------------------------------ -------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------- -------------------------------------- -----------------------------------
  *Streptococcus pneumoniae*              124 (60.8)                                 72/124                                                                           58.1                                         40                                                      112                                    90.3
  *Haemophilus influenzae*                56 (27.5)                                  52/56                                                                            92.9                                         2                                                       54                                     96.4
  *Neisseria meningitidis*                1 (0.5)                                    0/1                                                                              0                                            1                                                       1                                      100
  *Klebsiella pneumoniae*                 25 (12.3)                                  1/25                                                                             4                                            15                                                      16                                     64
  *Acinetobacter baumannii*               23 (11.3)                                  11/23                                                                            47.8                                         7                                                       18                                     78.3
  *Pseudomonas aeruginosa*                13 (6.4)                                   9/13                                                                             69.2                                         2                                                       11                                     84.6
  *Staphylococcus aureus*                 25 (12.3)                                  17/25                                                                            68                                           7                                                       24                                     96
  *Moraxella catarrhalis*                 27 (13.2)                                  24/27                                                                            88.9                                         2                                                       26                                     96.3
  *Legionella pneumophila*                2 (1)                                      1/2                                                                              50                                           0                                                       1                                      50
  *Mycoplasma pneumoniae*                 25 (12.3)                                  21/25                                                                            84                                           1                                                       22                                     88
  *Bordetella pertussis*                  3 (1.5)                                    3/3                                                                              100                                          0                                                       3                                      100
  Total[^a^](#TN1){ref-type="table-fn"}   167(81.9)                                  77/167                                                                           46.1                                         59                                                      136                                    81.4

*The total number of clinical samples is 204*.

###### 

Multiple infections verified by confirmatory tests.

  **Infection type[^a^](#TN2){ref-type="table-fn"}**   **No**.   **Infection type**   **No**.   **Infection type**             **No**.
  ---------------------------------------------------- --------- -------------------- --------- ------------------------------ ---------
  SP, HI                                               15        SP, HI, MC           4         SP, HI, KP, AB                 2
  SP, PA                                               5         SP, HI, AB           4         SP, MP, HI, SA                 1
  SP, MP                                               3         SP, HI, SA           3         HI, MC, KP, PA                 1
  SP, SA                                               3         SP, SA, MC           3         SP, MC, KP, AB                 1
  SP, MC                                               3         SP, MP, HI           3         SP, MP, MC, AB                 1
  SP, AB                                               2         SA, MC, KP           2         SP, MP, HI, KP                 1
  KP, AB                                               2         KP, PA, AB           1         SP, HI, MC, KP                 1
  MP, HI                                               2         SP, HI, PA           1         SP, HI, MC, NM                 1
  SA, KP                                               2         MP, HI, KP           1         SP, HI, SA, MC                 1
  SA, MC                                               1         SP, MP, MC           1         SP, BP, SA, AB                 1
  HI, KP                                               1         SP, MP, PA           1         Quintuple infections (n = 1)   
  HI, MC                                               1                                        SP, MP, HI, SA, MC             1

*SP, Streptococcus pneumoniae; LP, Legionella pneumophila; BP, Bordetella pertussis; MP, Mycoplasma pneumoniae; HI, Haemophilus influenzae; SA, Staphylococcus aureus; MC, Moraxella catarrhalis; KP, Klebsiella pneumoniae; PA, Pseudomonas aeruginosa; AB, Acinetobacter baumannii; NM, Neisseria meningitides*.

###### 

Samples with discordant results by the BP-MS method and the confirmatory tests.

  **Sample ID**   **BP-MS results[^a^](#TN3){ref-type="table-fn"}**   **Confirmatory tests results**
  --------------- --------------------------------------------------- --------------------------------
  S1              PA                                                  Negative
  S2              SP                                                  Negative
  S3              SP                                                  Negative
  S4              AB                                                  Negative
  S5              KP                                                  Negative
  S6              SP                                                  Negative
  S7              SP                                                  Negative
  S8              LP                                                  Negative
  S9              SP                                                  Negative
  S10             SP                                                  Negative
  S11             SP                                                  Negative
  S12             SP                                                  Negative
  S13             SP                                                  Negative
  S14             HI                                                  Negative
  S15             SP, SA, KP, AB                                      SP, SA, AB
  S16             SP, HI, AB                                          SP, HI
  S17             SP, AB                                              SP
  S18             HI, MC, KP, PA                                      HI, MC
  S19             SP, MP                                              SP
  S20             SP, HI, SA                                          SP, SA
  S21             SP, BP, HI                                          BP, HI
  S22             SP, MC, KP, AB                                      SP
  S23             SP, MP, HI, SA                                      SP, MP, HI
  S24             MP, PA                                              PA
  S25             SA, KP, AB                                          SA
  S26             SP, LP, KP                                          SP, LP
  S27             KP, AB                                              AB
  S28             SP, KP                                              KP
  S29             SP, MP                                              SP
  S30             SP, KP                                              Negative
  S31             SP, HI, KP, AB                                      SP, HI, AB

*SP, Streptococcus pneumoniae; LP, Legionella pneumophila; BP, Bordetella pertussis; MP, Mycoplasma pneumoniae; HI, Haemophilus influenzae; SA, Staphylococcus aureus; MC, Moraxella catarrhalis; KP, Klebsiella pneumoniae; PA, Pseudomonas aeruginosa; AB, Acinetobacter baumannii; NM, Neisseria meningitidis*.

Discussion {#s4}
==========

Pneumonia and meningitis can be caused by various bacterial pathogens; therefore, identifying the causative organism in a clinical case is challenging. Real-time PCR is a method frequently used for pathogen detection, but the limited optical channels restrict the number of targets that can be detected simultaneously. An optimized real-time PCR assay can be used to detect three to four targets in one reaction, which means that multiple reactions are needed to cover the spectrum of potential pathogens (Edin et al., [@B11]; Gadsby et al., [@B12]). Some sample-to-result platforms, such as the FilmArray (Biofire, Salt Lake City, UT, USA) system, provide another solution. The FilmArray system integrates sample preparation, amplification, detection, and analysis in one device, and the results can be obtained in 1 h, with 5 min of hands-on time. However, each FilmArray analyzer can process only one specimen per run, resulting in a high cost per specimen (Poritz et al., [@B34]; Babady, [@B3]).

One advantage of the BP-MS method established in this study is the comprehensive coverage of targets. Up to 11 pathogens can be detected simultaneously in one reaction, which is beneficial in respiratory illnesses with many possible etiologies and saves a substantial amount of labor. The high sample throughput of this method is another advantage. Using a 384-well PCR plate, as many as 380 clinical specimens can be analyzed within a single experiment, reducing the cost to \<\$4 per sample (not including nucleic acid extraction). Therefore, when many samples need to be tested, the BP-MS method is more feasible and economical than a FilmArray system.

The 11 target pathogens selected for use in the BP-MS method are the etiologic organisms most frequently detected in association with bacterial respiratory diseases. For community acquired pneumonia (CAP), *S. pneumoniae* is most often the cause, and other common bacterial causes include *H. influenzae* and *M. catarrhalis* (Musher and Thorner, [@B27]). *M. pneumoniae* and *L. pneumophila* are atypical CAP etiologies (Arnold et al., [@B1]). In contrast to bacteria associated with CAP, the dominant etiologic agents of hospital-acquired bacterial pneumonia are *S. aureus, P. aeruginosa, K. pneumoniae*, and *A. baumannii*, always showing less susceptibility to antimicrobials (Jones, [@B20]). In addition, *N. meningitidis* and *B. pertussis* are common causes of meningitis and pertussis. We have also designed assays for *Chlamydia pneumoniae*, which is an important atypical pathogen responsible for CAP. As isolates and positive clinical samples of *C. pneumoniae* are not available in this study, we have not evaluated its performance, so it is not included in the current panel.

Based on the sensitivity test, the limit of detection (LOD) of the BP-MS method is 10 gene copies/reaction. In this study, 31 samples positive for at least one of the target pathogens using the BP-MS method were not confirmed positive by either real-time PCR or nested PCR. We speculate that the different designs of the BP-MS method and confirmatory tests accounted for such discrepancies. Apart from methodological factors, the lower LOD with the BP-MS method may be attributable to the five additional cycles of primary multiplex PCR and dissimilar target selection (*H. influenzae* and *S. aureus*, Table [S2](#SM2){ref-type="supplementary-material"}). For target pathogens with low rates of concordance, such as *K. pneumoniae*, this disagreement may be attributable to differences in sensitivities of the BP-MS method and confirmatory tests.

The composition of the airway microbiota is driven by different ecological factors and is highly heterogeneous (Huffnagle et al., [@B17]). Some commensal bacteria such as *Streptococcus mitis, Streptococcus oralis*, and *Haemophilus haemolyticus* are closely related to pathogenic bacteria, which complicates accurate identification in certain individuals. Because of resource constraints, isolates of commensal bacteria were not included in the validation stage. The increase in detection with the BP-MS method relative for that with real-time PCR and nested PCR may be the results of cross-reactions with related species. Although we chose species-specific genes as targets to avoid cross-reactions, this possibility cannot be ruled out.

For CAP cases, multiple types of specimens should be used for microbial diagnosis (Johansson et al., [@B19]). A positive result from blood or pleural fluid (e.g., for meningitis, cerebrospinal fluid) samples by molecular test is of great value for pathogen identification. However, some substances present in blood, body fluids, and sputum may affect polymerase activity and inhibit amplification (Burd, [@B6]). Because of this, in the next stage of evaluation, various specimen types will be included.

The BP-MS method is a qualitative test, and its high sensitivity may allow asymptomatic carriage to be incorrectly interpreted as an etiological diagnosis. *S. pneumoniae* is the most commonly pathogenic bacteria carried in the nasopharyngeal cavity. The prevalence of *S. pneumoniae* carriage differs greatly between countries, ranging from 8.6 to 72%, and is higher in developing countries (Marchisio et al., [@B24]; Huang et al., [@B16]; Hill et al., [@B14]; Neves et al., [@B28]). Two recent studies indicate that the colonization rate of *S. pneumoniae* among healthy children in China is 16.6 to 26.6% (Hu et al., [@B15]; Pan et al., [@B29]), which means that for some cases of pneumonia, *S. pneumoniae* may not be the causative agent. Therefore, *S. pneumoniae* in a respiratory tract sample should be interpreted clinically, as is the case with other colonizing microorganisms such as *H. influenzae, S. aureus, M. catarrhalis*, and *N. meningitidis*. In this respect, a quantitative molecular test is more helpful in distinguishing etiological infection from asymptomatic carriage (Gadsby et al., [@B12]), whereas the BP-MS method can provide guidance on target selection for quantitative tests.

Using conventional and real-time PCR techniques, microbial etiologies can be identified in 65 to 86% of CAP cases (Thomson and Harris, [@B38]). For bacterial etiologies, detection rates are reported to be 58% by Johansson et al. ([@B19]) and 44.7% by Jones ([@B20]). Still nearly half of pneumonia cases, in which no causative agents can be detected (Mandell et al., [@B23]). In the present study, using the BP-MS method, the rate of bacterial pathogen detection was 81.9% (167/204), which indicates that this new method can assist determining the causative pathogens in cases with unknown etiologies.

Mixed infections have been reported by different groups, with the rate of bacterial coinfection varying from 13% to approximately 33%; the most common combination is *S. pneumoniae* and *H. influenzae* (de Roux et al., [@B10]; Cilloniz et al., [@B8]; Musher et al., [@B26]). Bacterial coinfection is associated with severe disease and high mortality rates, so timely discovery of mixed etiologies is critical for antimicrobial treatment and clinical outcomes (Cilloniz et al., [@B7],[@B8]; Kumagai et al., [@B21]). In our study, *S. pneumoniae* and *H. influenzae* were the most frequently identified coinfection bacteria, but multiple infections were found in 45.6% (93/204) of samples, which is higher than the percentage determined in other studies. In particular, we noticed that, when using real-time PCR alone, the concordance rate of results for samples with multiple infections was lower than that for single-infection samples. This finding suggests that the BP-MS method performs well in clarifying complicated polymicrobial etiologies.

In summary, with the advantages of its multiplex format and high sample throughput, the BP-MS method is a powerful tool that can be used for pathogen screening and may provide valuable information for antibiotic selection in early stages of disease.
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